

Daruka Mahadevan, MD, PhD
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Daruka Mahadevan, MD, PhD
Daruka Mahadevan, MD, PhD, is a professor of medicine at The University of Texas Health Science Center at San Antonio. He is the director of research and Co-Chair of the UT Health San Antonio Multispecialty and Research Hospital. He also is an internationally recognized physician-scientist in hematology and medical oncology.
He received his Bachelor of Science degree in physiology and biochemistry from the University of Reading, England. He went on to the University of London to earn his doctorate in protein crystallography. He received his Bachelor of Medicine, and Bachelor of Surgery (MD equivalent) from King’s College Hospital Medical School at the University of London. He completed his residency in internal medicine at the University of Connecticut Health Center, and his hematology-oncology fellowship at the University of Arizona Health Sciences Center. Dr. Mahadevan is board-certified by the American Board of Internal Medicine and the American Board of Medical Oncology.
Mahadevan’s major area of interest is early-phase treatments for patients with pancreatic cancer, gastrointestinal stromal tumors, myelodysplastic syndromes and non-Hodgkin’s lymphoma, including chronic lymphocytic leukemia. He has led or co-led early-phase clinical trials investigating cancer agents first being tested in humans with funding from several National Institutes of Health grants and foundations supporting cancer research. In addition, he has successfully directed a drug discovery laboratory program based on his expertise in protein crystallography. This has led to his being awarded six U.S. patents for new drugs he developed that target novel driver oncogenes (new cancer mutations that initiate or continue cancer).
One of the new drugs he developed, amuvatinib, targeting c-Kit/c-Met/PDGFR/RAD51 has gone through Phase I and II clinical trials. As PI or co-PI on several National Institutes of Health (NIH) and foundation grants, he has established proof-of-concept and delivered on drug discovery - R01 (AKT PH domain inhibitors) and on drug development - NSF (Prostate cancer translational drug development), SPORE in Lymphoma (Aurora kinase inhibitor therapy for aggressive lymphomas) and SWOG Hope Foundation (targeted therapeutics for aggressive B- and T-cell non-Hodgkin Lymphomas).
Lastly, he has participated in monthly scientific leadership committee meetings at UACC, NCI external advisory board (EAB) meeting (Feb 2016, CCSG renewal) and yearly EAB meetings. In addition, he received an NCI P30 supplement (2017-2019) to study rare cancers by whole-exome sequencing of tumor vs. normal in collaboration with the UA Genomics Core. From 2016 to 2019, he was the Director of the Early Phase Therapeutics Program (‘Phase I Program’) and enrolled over 150 patients in novel first-in-human investigational agents in both solid and hematologic malignancies.
He continues to expand the bandwidth of the early-phase therapeutics portfolio and Investigator Initiated Studies.
Gender
- Male
Languages Spoken
- English
-
Credentials
Credentials
Positions
- Professor of Medicine, University of Texas Health Science Center San Antonio
- Chief, Division of Hematology-Medical Oncology, University of Texas Health Science Center San Antonio
- Director, Institute for Drug Development, UT Health San Antonio MD Anderson Cancer Center
- Associate Director, Clinical Research, UT Health San Antonio MD Anderson Cancer Center
Certifications
- American Board of Internal Medicine, Medical Oncology
Education
Medical School: King's College Hospital Medical School, University of London, England, UK
Fellowship: Hematology/Oncology, University of Arizona College of Medicine, Tucson, AZ
Residency: Internal Medicine, University of Connecticut School of Medicine, Farmington, CT
Doctorate: Protein crystallography, Birkbeck College, University of London, England, UK
Fellowship: Research, National Institute of Health, Bethesda, MD - Locations & Contact
-
Research & Publications
Research & Publications
A comparative analysis of tumors and plasma circulating tumor DNA in 145 advanced cancer patients annotated by 3 core cellular processes
Larson K, Kannaiyan R, Pandey R, Chen Y, Babiker HM, Mahadevan D.
Cancers (Basel). 2020 Mar 16;12(3):701. doi: 10.3390/cancers12030701. PMID: 32188081; PMCID: PMC7140098.
View All Research & Publications
-
Clinical Trials
Clinical Trials
Type of Cancer
Carcinoma
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
Type of Cancer
Chronic Lymphoid Leukemia, Lymphoma
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Daruka Mahadevan, MD, PhD
A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
M22-716 is a Phase 1, FIH, open-label, dose escalation, dose expansion, biomarker/pharmacodynamic (PD) study of ABBV-319 in participants with relapsed or refractory (R/R) B-cell malignancies.
Type of Cancer
Solid Tumor
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Daruka Mahadevan, MD, PhD
A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients with Advanced or Metastatic Solid Tumors
To evaluate the safety, tolerability, MTD and the RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available.
Type of Cancer
Solid Tumor, Metastases
ClinicalTrials.gov Identifier
NCT06244771
Principal Investigator
Daruka Mahadevan, MD, PhD
An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants with KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors (PROSPER)
This is an open-label, Phase 1/2, dose escalation, dose expansion and cohort expansion study to evaluate the safety, tolerability, PK, PD and clinical activity of FMC-376 in participants with locally advanced unresectable or metastatic solid tumors which harbor KRAS G12C mutation.
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Daruka Mahadevan, MD, PhD
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY FOR LNCB74, A B7-H4 TARGETED ANTIBODY DRUG CONJUGATE, AS MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
The first-in-human clinical study will be a Phase 1, multicenter, open-label, multiple dose, two-part study of LNCB74 that will include Dose Escalation (Part 1) and Dose Expansion/Optimization (Part 2). The objectives of this study will be to determine the safety and tolerability, define the maximum tolerated dose (MTD), maximal administered dose (MAD) and/or the recommended Phase 2 dose (RP2D),…